



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification⁵ : C12N 15/62, 15/82, C12P 21/02 C12N 15/14, 15/29, 5/10 A01H 5/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 91/02066</p> <p>(43) International Publication Date: 21 February 1991 (21.02.91)</p>
<p>(21) International Application Number: PCT/NL90/00108</p> <p>(22) International Filing Date: 26 July 1990 (26.07.90)</p> <p>(30) Priority data: 8901932 26 July 1989 (26.07.89) NL</p> <p>(71) Applicant (for all designated States except US): MOGEN INTERNATIONAL N.V. [NL/NL]; Einsteinweg 97, NL-2333 CB Leiden (NL).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): SIJMONS, Peter, Christiaan [NL/NL]; Valeriusstraat 210-3, NL-1075 GK Amsterdam (NL). HOEKEMA, Andreas [NL/NL]; Warmonderweg 66, NL-2341 KX Oegstgeest (NL). DEKKER, Bernardus, Martinus, Maria [NL/NL]; Helena Hoeve 40, NL-2804 HZ Gouda (NL). SCHRAMMEIJER, Barbara [NL/NL]; Balsemkruid 21, NL-3068 DA Rotterdam (NL). VERWOERD, Teunis, Cornelis [NL/NL]; Oude Singel 268, NL-2312 RK Leiden (NL). VANDEN ELZEN, Petrus, Josephus, Maria [NL/NL]; Cayennehof 26, NL-2215 BH Voorhout (NL).</p>		<p>(74) Agent: SMULDERS, Th., A., H., J.; Verenigde Octrooibureaux, Nieuwe Parklaan 107, NL-2587 BP The Hague (NL).</p> <p>(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.</p> <p>Published With international search report. Before the expiration of the time limits for amending the claims and to be republished in the event of the receipt of amendments.</p>
<p>(54) Title: PRODUCTION OF HETEROLOGOUS PROTEINS IN PLANTS AND PLANT CELLS</p> <p>(57) Abstract</p> <p>This invention provides for a method to produce excreted and correctly processed heterologous protein-material in a plant host. The method comprises the step of transforming a plant host using a recombinant polynucleotide, which comprises the DNA sequences encoding the fully processed heterologous protein material, directly preceded by a DNA sequence coding for a plant signal peptide, and regulatory sequences necessary for the plant host to express the heterologous gene construct, resulting in excretion of the heterologous protein from the cell and correct cleavage of the N-terminal signal peptide, so that the mature heterologous protein produced by the plant host is identical to the corresponding protein produced in its authentic host.</p>		

* See back of page

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	PL	Poland
CA	Canada	JP	Japan	RO	Romania
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
DE	Germany	LU	Luxembourg	TD	Chad
DK	Denmark			TC	Togo
				US	United States of America

Production of heterologous proteins in plants and plant cells

Field of the invention

The present invention is in the field of recombinant DNA technology, more in particular recombinant DNA technology
5 concerning the genetic manipulation of plants and is related to a process for the production of proteins or polypeptides using genetically manipulated plants or plant cells, as well as to the genetically manipulated plants and plant cells per se (including parts of the genetically manipulated plants), the heterologous
10 protein material (e.g. a protein, polypeptide and the like) which is produced with the aid of these genetically manipulated plants or plant cells, and the recombinant polynucleotides (DNA or RNA) that are used for the genetic manipulation.

15 State of the art

One of the results of biotechnology is the development of new production methods for proteins. In virtue of this, it is possible to accomplish that, on a preparative scale,
20 microorganisms containing recombinant DNA produce proteins which these microorganisms naturally do not synthesize, or naturally do not synthesize in those quantities. Recent examples are in particular insulin, various interferon types and human growth hormone that are produced in commercial quantities by, among
25 others, bacteria and yeast cells.

Characteristic for these examples is the fact that this often concerns relatively simple polypeptides that do not require co- or post-translational processing within the cell, to obtain their final form and biological function. For a large
30 number of more complex proteins of higher organisms, such a

processing is of concern for the functioning of those proteins. For example, they need to be correctly glycosylated or undergo a membrane passage during which signal peptides are split off from a precursor ('precursor-protein'). In prokaryotic microorganisms
5 this is not possible, due to which higher organisms such as fungi have to be used.

Proteins synthesized on the rough endoplasmatic reticulum (ER) are excreted by the eukaryotic cell or stored at specific locations in the excretion route like the ER, Golgi complex,
10 plasma membrane or vacuole/lysosome (Pfeffer & Rothman, 1987). The choice of the excretion route is determined by the presence of a hydrophobic, amino-terminal signal peptide that is cleaved off from the precursor-protein. Examples of this are signal
15 peptides for invertase (Carlston & Botstein, 1982) or α -factor (Herskowitz & Oshima, 1982) that cause the respective mature protein products to reach the periplasmic space. Recently it was shown that signal peptides can also be used to achieve excretion of human proteins by yeast cells, although in that case processing is not complete (Stetler *et al.*, 1989).

20 From the experiments with the synthesis of animal proteins in fungi, it appeared that the use of fungal signal peptides gives more efficient processing and excretion than animal signal peptides, which means that a signal peptide, derived from the fungus which is acting as host, is functioning better (Kingsman
25 *et al.*, 1987; Harkki *et al.*, 1989).

For the transport to the lysosomes in mammals (Kornfeld., 1987), or vacuoles in yeast (Johnsson *et al.*, 1987) and plant cells (Dorel *et al.*, 1989) additional information is required that is located in part of the sequence of the mature protein
30 itself.

The knowledge of signal peptides for the excretion by plant cells is still very limited (Della-Cioppa *et al.*, 1987). Such signal peptides have only been described for 2 extensins from carrot (Chen & Varner, 1985) and tobacco (memelink, 1988), as
35 well as for three pathogenesis-related (PR) proteins from tobacco (Hooft van Huijsduijnen *et al.*, 1985; Cornelissen *et al.*, 1986); De Loose *et al.*, 1988). From this small number of

signal peptides no consensus has been obtained on the characteristics of cleavage- or recognition-sites. Neither has it become clear whether proteins, that are foreign to the plant, can be excreted by plant cells, nor if the processing of the
5 signal peptide occurs correctly when a fusion construct between a plant signal peptide and a heterologous protein would be used.

It has nevertheless been shown that plants are also a candidate as a production system for heterologous proteins. However, till now only the production of non-complex proteins in
10 plants has been shown (Goodman *et al.*, 1987; Misra, 1989).

EP-A-0 255 153 describes the isolation and identification of a gene encoding a pre-pro form of an alpha-galactosidase from guar seed. Said gene may be expressed by other plants, such as tobacco plants. It is concluded from Western blotting results,
15 mobility determinations and observation of alpha-galactosidase activity in culture supernatants that the pre-pro form of alpha-galactosidase, as encoded by the transferred gene, is secreted and correctly processed to the mature form when expressed by tobacco callus.

This reference teaches that a plant gene, if transferred as a whole, including its own pre-pro sequences, into another plant species, may be expressed, secreted and correctly processed therein. It does not teach, however, whether less related genes, such as genes of animal or human origin, may be expressed,
20 secreted and correctly processed in plants.

The expression of a heterologous gene in plant cells is disclosed in EP-A-0 270 248, which describes a DNA construct comprising a downstream coding sequence preceded by an upstream base sequence. The downstream coding sequence codes for a
30 protein which is desired to be transported to a plant cell wall. The bacterial beta-glucuronidase gene is used as a model gene, because its expression can be directly detected. The upstream base sequence codes for a cell wall targeting protein consisting of the leader sequence (or part of it) of the polygalacturonase precursor. Said polygalacturonase (PG) is an enzyme of plant
35 origin which is involved in the ripening of climacteric fruit. Two kinds of DNA constructs are disclosed in this reference: one

contains a DNA fragment encoding the complete leader of PG and the first six amino acids of the mature PG protein as the upstream base sequence, the other construct contains only a part of the PG leader sequence as the upstream base sequence; the
5 last 22 codons of the PG leader sequence are missing.

The reference does not show whether the fusion protein is secreted and processed correctly, i.e. cleaved at the correct cleavage site. It is conceivable that excretion and even some form of processing occur, but it does not seem likely that the
10 processing will be fully correct.

The use of an upstream base sequence encoding a signal peptide of plant origin for obtaining secretion of a bacterial protein by transformed plant cells is suggested also by Passiatore *et al.*, J. Cell. Biochem. Suppl. 13D, 27 March -
15 7 April 1989, page 267, Abstract M145, but again it is not shown whether the fusion protein is secreted and correctly processed. The exact structure of the DNA constructs, which comprise a bacterial chitinase gene preceded by extensin and proteinase inhibitor I leader sequences of plant origin, is not shown,
20 either.

EP-A-0 307 841 relates to the regulatory sequences of the pathogenesis-related (PR) protein genes of the PR-1 group and discloses an inducible PR-1 promoter and PR-1 secretion signal sequences. It is suggested that the PR-1 signal sequences may be
25 used to regulate in plants the secretion of heterologous proteins. However, it is not shown that such fusions are indeed functional. At that time it was far from predictable whether the combination of mature sequences and signal sequences from very divergent systems (such as plants and humans) would indeed give
30 rise to a correct cleavage of the signal peptide, resulting in a mature heterologous protein with exactly the same N-terminus as the wildtype protein. A correct cleavage appears to be dependent on the amino acid sequences flanking the cleavage site. Therefore, this reference does not show that, nor how, a correct
35 processing of animal and human proteins, such as HSA, could be obtained in plants.

EP-A-0 091 527 discloses the production of HSA-like peptides in *E. coli* as a host. Although it is suggested that other host organisms may be used, including other bacteria, yeasts, fungi, animal and plant hosts, it is also expressly stated therein that "hosts may lack the appropriate enzymes which may be required to transform the host-produced polypeptide to the structure and substitution of natural HSA". This reference also suggests quite generally that the HSA gene may be combined with various signal sequences, both prokaryotic and eukaryotic, as to permit secretion of the HSA from the cells of the transformed host. Instead of giving details and experimental evidence, however, a reference is made to Villa-Komaroff *et al.*, "A bacterial Clone synthesizing Proinsulin", P.N.A.S. USA 75, 1978, pp. 3727-3731, and to Talmadge *et al.*, "Eukaryotic Signal Sequence Transports Insulin Antigen in *Escherichia coli*", P.N.A.S. USA 77, 1980, pp. 3369-3373. These references do not disclose any methods of producing excreted and/or correctly processed animal proteins in a plant host, however.

Therefore, it is still unclear whether plants or plant cells are suited for the expression of heterologous proteins that require co- or post-translational processing.

Description of the invention

According to the invention it was found that a heterologous, for example non-plant, protein can be excreted by transgenic plant cells using a plant signal peptide. The protein human serum albumine (HSA) has been selected as an example of a protein that during excretion requires a complex in vivo processing. HSA is the main component of blood plasma. It is a protein of 585 amino acids when it is fully processed, it contains 17 disulfide bridges (Bherens *et al.*, 1975). In order to obtain processing, a passage across a cell membrane must take place, during which a signal peptide is cleaved off and the protein can obtain its proper folding. Proteins that are excreted by their natural host are supposed not to fold or to fold incorrectly when they are synthesised intracellularly.

Excretion is a prerequisite to establish the correct folding of the disulfide bridges.

Till now, HSA is purified from blood-plasma according to a conventional method. The protein is being used in quantities in the order of grams for the replacement of blood in cases of trauma and several clinical situations. For a couple of reasons the production of HSA in a recombinant host is very attractive. In the first place to eliminate the risk of spreading infectious diseases (like AIDS and hepatitis) during HSA-treatment and in the second place to reduce the dependance on available blood. The protein HSA is synthesised intracellularly in Escherichia coli (Latta *et al.*, 1987) and also expressed and excreted in Bacillus subtilis (Saunders and Guyer, 1987). Excretion of HSA has been proven in transgenic yeast cells of Saccharomyces cerevisiae (Etcheverry *et al.*, 1986).

According to the invention plant signal peptides are used, in particular those obtained from PR-proteins, in fusion constructs with especially non-plant proteins for the production of extracellular proteins in plants or plant cell cultures. As an example of a useful plant signal peptide, a signal peptide was used derived from the thaumatin-like PR-protein, encoded by PROB12 from tobacco (Cornelissen 1986), coding for a hydrophobic N-terminal peptide of 24 amino acids.

According to the invention a plant signal peptide can be used for the following goals:

- a) production in plants or plant cells of proteins that require processing for their physiological action (for instance human serum albumine),
- b) production in plants or plant cells of proteins that require excretion for economical or process-technical reasons (for example for the cheap isolation from the culture medium of the suspension cells),
- c) production of proteins that need to have their function in the extracellular space (for example for the introduction of genes coding for proteins that provide the plant with resistance against pathogens that invade via the extracellular spaces or colonize said spaces).

On behalf of the production of recombinant proteins the final choice of the production organisms will depend on economic parameters such as the culturing, growth and purification costs. Till now plants have not been used for the production of

5 proteins, although they represent a cheap source of biomass. Production of heterologous proteins in plants can be a cheap alternative to the use of microorganisms, especially in those cases where the extraction of the protein can be fitted into an existing industrial process. The costs of growing modified

10 plants are low in comparison with the costs of fermentation or microorganisms or animal cell cultures, and even neglectable, when the plant is already used for the production of bulk vegetable substances. The starch industry (maize, tapioca, potato, cassava) is particularly suitable for co-production of

15 heterologous proteins, because the first steps of the existing procedure of the starch extraction do not involve denaturing conditions. The protein fraction is held in solution in the extracted cell juice at low temperatures. This protein-rich juice stream is a waste product of the starch industry and is,

20 especially for environmental reasons, only processed to animal fodder. To introduce a protein-purification step, the starch extraction process requires no, or hardly any, modification; consequently, due to the introduction of commercially interesting, heterologous proteins in this juice stream a very

25 cheap source of such proteins is obtained. In addition, this preferred embodiment of the invention augments the economic value of the waste stream. Obviously, for proteins with a high economic value, a similar production method can be applied on a smaller scale and starch production be of secondary importance.

30 In a broad sense, the invention thus provides a process for the production in a plant host of heterologous protein material which is to be excreted from the cells in which it is produced, by growing plants or plant cells that, by means of genetic manipulation, optionally of an ancestor, using a recombinant

35 polynucleotide, have been provided with the genetic information which is required to allow the plant host to express the heterologous protein material and excrete it from the cells in

which it is formed, the genetic information introduced into the host comprising an expression cassette that is functional in the host cell and contains at least a gene coding for the mature protein material, directly preceded by genetic information
5 coding for a plant signal peptide that is functional in the host.

Preferred, according to the invention, is a process in which a protein material is produced that, in its natural environment, originates from a precursor which contains a signal
10 peptide that provides for excretion from the cell and which itself is cleaved off, the genetic information introduced into the plant host comprising an expression cassette which is functional in the host and contains a gene construct comprising the gene encoding the mature protein material and, directly
15 preceding it, genetic information coding for a plant signal peptide that is functional in the host, instead of the genetic information coding for the natural signal peptide of the heterologous protein material.

The expression 'protein material' refers to material such
20 as polypeptides and proteins, whether or not glycosylated. The expression 'heterologous protein material' refers to protein materials that are foreign to the selected plant host, e.g. are naturally not produced in this host. Although the heterologous protein material to be produced can in principle be from plant
25 origin, or even originate from yeast, the invention is focussed in particular on the use of a plant host for the production of animal or human protein materials, especially the more complex proteins that require one or more post-translational processing steps. Consequently, according to the invention, it is preferred
30 that the protein material produced be an animal or human protein which requires one or more post-translational processing steps, including at least an excretion from the cells in which the protein is produced in the form of a precursor containing a signal peptide preceding the mature protein, and a cleavage of
35 this signal peptide. In a particularly preferred embodiment of the invention the protein material produced is human serum albumine.

The words 'optionally of an ancestor' refer to the fact that plants are living beings, which implies that the genetic information required for production of the heterologous protein material, introduced into the first transgenic plants or plant cells, e.g. the first generation of the manipulated plants, may also be present in the progeny. Obviously, also these and later generations of the transgenic plants and plant cells may be used for the production of heterologous protein material.

The words 'recombinant polynucleotide' indicate DNA and RNA constructs that are the result of techniques as such known in recombinant DNA technology. Presently, most transformation methods are based on the use of recombinant DNA, for example in the form of plasmids, so that the recombinant polynucleotide to be used preferably consists of recombinant DNA, but the invention is not limited thereto and, consequently, also covers methods of genetic manipulation in which recombinant RNA is put into practice.

The expression 'expression cassette' is conventional and refers to a combination of regulatory elements that are required by the host for the correct transcription and translation (expression) of the genetic information contained in the expression cassette. These regulatory elements comprise a suitable (i.e. functional in the selected host) transcription promoter and a suitable transcription termination sequence.

As was mentioned before, according to the invention it is preferred, that the genetic information introduced into the plant host comprises an expression cassette that is functional in the host and contains a gene construct comprising a gene encoding the mature protein material and, directly preceding it, genetic information coding for a plant signal peptide that is functional in the host and is derived from the pathogenesis-related protein PROB12. This plant signal peptide proved in different plant species to accomplish a correct excretion from the cell, a correct cleavage of the signal peptide and a correct folding of the mature protein material.

With respect to the nature of the host, the invention, in principle, does not impose any limitations other than practical

limitations of temporary character, related to the fact that methods for the transformation of certain plant species have not been developed yet. In a very special preferred embodiment of the invention a plant that is suitable for the production of starch is used as a host. In relation to this, one should think in the first place of plants selected from the group consisting of potato, maize, and cassava. According to the invention it is especially preferred, that the plant host used is a potato variety suitable for industrial starch production and that its tubers are used for both the extraction of starch and the production of the heterologous protein material.

According to the invention, it is also possible to use plant cells in suspension culture as the plant host. Plant cell suspension cultures are known *per se*. According to the invention it is very useful to use a suspension culture of plant cells of the plant species tobacco as the plant host.

In the experimental part some specific Examples according to the invention are given. These Examples are 1) a process for the production of human serum albumine by growing potato plants that, by means of genetic manipulation, optionally of an ancestor, using a recombinant polynucleotide, have been provided with the genetic information required to allow expression and correct post-translational processing of the human serum albumine by the potato plants, the genetic information introduced into the potato comprising an expression cassette that is functional in the potato and contains at least a gene coding for human serum albumine, directly preceded by genetic information coding for a plant signal peptide that is functional in the potato and is derived from the pathogenesis-related protein PRO12, and extracting the human serum albumine produced from the genetically manipulated potato tubers, and 2) a process for the production of human serum albumine by growing in suspension cells of the plant species tobacco that, by means of genetic manipulation, optionally of an ancestor, using a recombinant polynucleotide, have been provided with the genetic information required to allow the suspended tobacco cells to express and correctly post-translationally process the human

serum albumine, the introduced genetic information comprising an expression cassette suitable for expression in tobacco and containing at least a gene coding for mature human serum albumine, directly preceded by genetic information encoding a plant signal peptide that is functional in tobacco and is derived from the pathogenesis-related protein PROB12, and extracting from the culture medium the human serum albumine produced by the genetically manipulated, suspended tobacco cells.

More in particular, the experimental part shows, that cells derived from potato or tobacco plants have been transformed using a vector containing a marker gene for kanamycin selection, as well as a gene coding for human serum albumin (HSA), preceded by either the natural HSA signal sequence (for comparison), or the signal sequence of a plant pathogenesis-related protein. Also, electroporation experiments were carried out on protoplasts of tobacco plants. These experiments aimed at obtaining an excretion of HSA across the plasma membrane of the transgenic plant cells. During the excretion process, the HSA protein is modified to a form in which the protein obtains its physiological function.

After transformation, expression has been demonstrated in all the investigated plant parts (potato: leafs, stem, stalks and tubers, the latter both fresh as well as after 2 weeks of storage at 4°C as is usual with industrial potato's; tobacco: leafs, callus and suspension cells). Excretion of HSA by transgenic cells was proven with three methods:

- a) after electroporation of tobacco protoplasts with chimaeric HSA-gene constructs, HSA could specifically be detected in the culture medium using Western blotting. In extracts of the transgenic tobacco protoplasts no HSA could be detected.
- b) callus (undifferentiated cell material) was derived from HSA-transgenic tobacco plants. With this callus a suspension culture was set up. In extracts of tobacco suspension cells no HSA protein could be detected.
- c) After transformation of potato with the constructs mentioned above and after regeneration of adult potato plants, HSA could

be detected with high specific concentration in the extracellular fluid isolated from transgenic leaf material. The extraction of extracellular fluid from leaf material was monitored using cellular and extracellular marker enzymes. With all three test methods mentioned above (a, b & c) it appeared, that both the human and the plant signal peptide can lead to excretion of HSA. However, it appeared from amino acid analyses of HSA isolated from transgenic plants that only the plant signal peptide resulted in a correct processing (i.e. removal of the signal peptide at the right cleavage site).

The functioning of the heterologous constructs as described in the experimental part proves that a signal peptide of a PR-protein can establish excretion and correct processing of heterologous proteins to the extracellular space.

Description of the figures

Fig.1 A survey map of the constructs that were used for the chimaeric HSA-genes. On the schematic restriction maps are indicated, from left to right: the enhancer and promoter (2 open boxes), ALMV leader (thick line), signal sequence (dotted box), structural HSA gene (black box) and nos terminator (thin line). The restriction sites are indicated by one-character codes.

Fig.2 Schematic outline of the construction of plasmid pMOG18. The different plasmids are not depicted in proportion.

Fig.3 Schematic outline of the construction of plasmid pMOG36. The different plasmids are not depicted in proportion.

Fig.4 Schematic outline of the construction of plasmid pMOG49 and pMOG50. The different plasmids are not depicted in proportion. The sequence in the box, which codes for an alanine-residue, has been used for the construction of pMOG48.

Fig.5 Schematic outline of the construction of plasmid pMOG85. The different plasmids are not depicted in proportion.

Experiments

I Construction of chimaeric HSA-genes for the expression in plants

5

For the expression of the human gene for serum albumin (HSA) the following regulatory sequences were used:

- 1) The constitutive 35S promoter derived from the cauliflower mosaic virus (CaMV, Guilley *et al.*, 1982), equipped with a double enhancer for optimal gene-expression.
- 2) The transcription-termination sequence derived from the gene coding for nopaline synthase (nos) of the pTiC58 plasmid from *Agrobacterium tumefaciens* (Bevan, 1984).
- 3) The 5' leader sequence of the alfalfa mosaic virus (ALMV, Brederode *et al.*, 1980) for stabilisation of the chimaeric messenger RNA. A fusion was made between the leader sequence and the sequences coding for the HSA (fig.1). An overview map of the four constructs used is given in figure 1.

- The construction of the different plasmids via standard recombinant DNA-techniques (Maniatis *et al.*, 1982) started from pMOG18 (fig.2). This plasmid is derived from *E. coli* vector pUC18 (Yanisch-Perron *et al.*, 1985), which contains in the polylinker the CaMV 35S promoter/enhancer, followed by the AMV leader sequence, the gene for β -glucuronidase (Sleat *et al.*, 1987) and the nos-terminator (Bevan, 1984). This plasmid was derived as is indicated in fig.2. The expression-cassette, consisting of the CaMV 35S promoter and the nos-terminator was placed in plasmid pUC18 (=pMOG3) as EcoRI-HindIII fragment (derived from plasmid pROK1; Baulcombe *et al.*, 1986).
- Subsequently, the 5' proximal region of the 35S promoter was removed by blunt-ending the NcoI-site in the promoter using Klenow polymerase, and reducing the length of the plasmid, via digestion with EcoRI and insertion of the EcoRI-linker, resulting in plasmid pMOG4. The BamHI-HindIII fragment from plasmid pMOG4 was replaced with a synthetic fragment containing the leader-sequence of the alfalfa mosaic virus (ALMV). The indicated NcoI-site in the synthetic fragment is located

directly downstream of the ALMV-leader and contains the ATG translation-initiation codon. In the obtained plasmid pMOG11 the BamHI-HindIII-fragment with the nos-terminator was reinserted, resulting in plasmid pMOG12. A gene coding for β -glucuronidase
5 (derived from plasmid pRAJ275; Jefferson, 1987) was placed in plasmid pMOG12 as a NcoI-BamHI fragment, resulting in plasmid pMOG14. Finally, the enhancer sequence of the 35S promoter, located on a AccI-EcoRV fragment from pMOG14, was isolated, blunt-ended with Klenow polymerase and placed in the blunt-ended
10 EcoRI-site of pMOG14, which resulted in plasmid pMOG18 containing a double enhancer sequence (fig.2).

The HSA-protein is naturally synthesized as a precursor (Judah *et al.*, 1973), in which the mature protein of 585 amino acids is preceded by a 'prepro'-peptide of 24 amino acids. The
15 cloned preproHSA cDNA (Lawn *et al.*, 1981) was used as starting material for the construction of pMOG36, in which the sequence coding for the HSA-protein is preceded by the human HSA-prepro-peptide (Lawn *et al.*, 1981). Also, the sequence coding for the mature HSA-protein was fused in two different ways to a signal
20 peptide of plant origin (plasmids pMOG49 and pMOG50). Finally, a HSA-gene was made that did not contain a sequence coding for a signal peptide (plasmid pMOG85).

25 a) Construction of plasmid pMOG36, containing preproHSA

As is indicated in fig.3, the sequence coding for preproHSA was cloned as a Bst EII-ClaI-fragment. The restriction site for Bst EII (GGTAACC) is located nine nucleotides behind the start codon of the HSA gene (Lawn *et al.*, 1981). Using standard
30 techniques, a restriction site for ClaI was created, 27 bp behind the TAA stopcodon of the HSA-gene by mutation of the sequence TACCAT to ATCGAT, using M13-vectors (Yanisch-Perron *et al.*, 1985). Due to this, the Bst EII-ClaI fragment had a size of 1850 bp. A synthetic NcoI-BamHI fragment of 29 bp was placed in
35 pMOG18. In the resulting plasmid pMOG33, directly behind the ATG startcodon, the missing 9 nucleotides till the Bst EII-site, followed by a ClaI-site, were present. In plasmid pMOG33 the

preproHSA gene was placed as is indicated in fig.3, resulting in plasmid pMOG36.

- b) Construction of the plasmids pMOG49 and pMOG50, containing
5 a fusion of the PROB12 signal peptide to the mature HSA-protein

The sequence coding for the mature HSA-protein was fused in two ways to the signal peptide of the PR-protein PROB12 from Samsun NN tobacco (Cornelissen *et al.*, 1986). This plant signal
10 peptide has a length of 25 amino acids and an Ala-Ala peptide binding constitutes the cleavage-site of the signal peptide and the mature PROB12 protein. The cleavage-site of the 24 amino acid prepro-sequence of HSA and the mature HSA is Arg-Asp (Lawn *et al.*, 1981). In the constructions presented here two different
15 fusions were made between the PROB12 signal peptide and the mature HSA, viz. a fusion between the last amino acid of the PROB12 signal peptide and the start of the mature HSA (Ala-Asp), and a fusion in which the mature HSA is preceded by the cleavage-sequence of the PR-protein (Ala-Ala-Asp, fig.4).

20 For the construction of plasmids pMOG49 and pMOG50, on the 9th and the 10th codon of the mature HSA the sequence CAT CGG T was mutagenised into CAT CGA T by means of standard procedures (Kunkel, 1985) using M13-vectors (Yanisch-Perron *et al.*, 1985). Concomitantly, a ClaI restriction site was created without
25 changing the encoded protein (fig.4); the correct mutagenesis was confirmed by sequence analysis. The fusion of the plant regulatory signals started from plasmid pMOG18, in which a synthetic NcoI-BamHI fragment of 80 bp was placed, which fragment codes for the signal peptide of PROB12, from the ATG
30 start codon till the SphI restriction-site that is located directly in front of the first Ala-residue of the cleavage-site (Cornelissen *et al.*, 1986). In the resulting plasmid pMOG42, finally, two different synthetic linkers were placed, coding for, on the one hand, a Ala-Ala-Asp fusion with the mature HSA-
35 gene till the created ClaI restriction-site in the 9th and 10th codon of the mature protein, on the other hand for the corresponding Ala-Asp fusion. In the resulting plasmids pMOG48

and pMOG43, subsequently, the mutagenised HSA-gene was placed as ClaI-fragment, resulting in the plasmids pMOG49 and pMOG50, respectively.

5 c) Construction of plasmid pMOG85, containing mature HSA

Using standard procedures (Kunkel, 1985) the HSA-gene was mutagenised in a M13-derived vector in such a way that in the coding sequence the first amino acid of the mature protein (Asp) was preceded by a NcoI restriction-site, containing an ATG translation-start codon in the correct reading frame (fig.5). The HSA-gene thus derived, including the NcoI restriction-site, was checked on DNA-sequence and subsequently subcloned in plasmid pMOG18 (fig.5). The NcoI-BamHI fragment, containing the C-terminal region of the HSA-gene, was isolated from plasmid pMOG50 and placed in vector pMOG18, resulting in plasmid pMOG4HSA. The first 742 bp of the HSA-gene, including the created ATG startcodon, was placed in plasmid pMOG4HSA as a NcoI-fragment. The resulting plasmid pMOG85 now contained the mature HSA-gene without the signal peptide sequence in the expression vector.

The plasmids pMOG36, pMOG49, pMOG50 and pMOG85 contained now the HSA-gene to be introduced as a 3,0 kb EcoRI-HindIII restriction fragment.

II Electroporation of tobacco protoplasts

The isolation and electroporation of tobacco protoplasts (Nicotiana tabacum cv. SR1) was carried out according to Rodenburg et al. (1989). For the electroporation 5×10^5 protoplasts were suspended in 0.5 ml buffer, preincubated during 10 minutes at 0°C in the presence of 40 µg/ml supercoiled DNA of one of the plasmids pMOG36, pMOG49, and pMOG50 and subsequently electroporated at 300 V/cm and one pulse of 38 msec. After again 10 minutes at 0°C, the cells were diluted in 5 volumes K3G medium and further grown in the dark at 20°C. The presence of the HSA-protein was tested as described in VI.

III Transformation of tobacco and induction of suspension cells

For the introduction of gene-constructs in plants, various techniques are available such as transformation with

5 Agrobacterium tumefaciens or Agrobacterium rhizogenes, micro-injection, particle bombardment, DNA-uptake in protoplasts, etc. The actual method of introduction of DNA is not critical with respect to the invention. For the transformation of tobacco, cocultivation of leaf-disks with Agrobacterium tumefaciens was

10 used according to the procedure of Horsch et al. (1985). This method is based on the principle of the binary vector system (Hoekema et al., 1983), in which Agrobacterium strains are used that on the one hand contain a plasmid, on which the virulence (vir) genes are located and on the other hand, a plasmid

15 compatible with it, that contains the gene to be introduced. The four relevant gene-constructs as they are present on the plasmids pMOG36, pMOG49, pMOG50 and pMOG85 were cloned in the binary vector pMBV4. This vector can replicate both in E. coli and in Agrobacterium, is derived from the binary vector Bin19

20 (Bevan, 1984) and does not differ from it on points that are essential for the present invention. Vectors pMBV4 and Bin19 contain between the left and the right border sequence of the T-DNA an identical chimaeric NPTII-gene encoding kanamycin-resistance (Bevan, 1984), as well as a so-called polylinker for

25 the cloning of the construct to be integrated. The chimaeric HSA-genes located on the plasmids pMOG36, pMOG49, pMOG50 and pMOG85 were placed in the polylinker of the vector pMBV4 as a 3.0 kb EcoRI-HindIII-fragment, after the vector was linearised with EcoRI and HindIII. The binary plasmids thus obtained,

30 respectively pMOG236, pMOG249, pMOG250 and pMOG285 were now, by means of mobilisation using the plasmid pRK 2013 (Ditta et al., 1980), transferred to an Agrobacterium strain, containing a plasmid carrying the vir-genes for the transfer of the T-DNA to the plant.

35 Using the Agrobacterium strains thus obtained, transformation of tobacco was carried out. Transgenic plants were regenerated from shoots that developed on selection-medium

(100 mg/l kanamycin). The presence of HSA-protein was tested as described hereafter, in VI. A suspension culture was initiated from the transgenic plants that showed the highest expression level (clone pMOG249#1). To this end, callus was induced on
5 transgenic leaf disks by growing on MS medium, 3% sucrose (MS30), 2.0 mg/l NAA, 0.1 mg/l kinetine and 50 mg/l kanamycin, after which the callus was transferred to liquid medium of the same composition. After one week in suspension, the medium was replaced with new MS30, now containing 0.5 mg/l 2,4-D. This
10 medium was refreshed every week till a homogeneous culture had been obtained. From the 7th week onwards the kanamycin selection was increased in steps of 25 mg/l to 100 mg/l.

IV Transformation of potato

15

For the transformation of potato, the binary vector system was used, developed for Agrobacterium tumefaciens as described above under III. Tuber-disks of the cultivar Desiree were cocultivated with the Agrobacterium strains containing the
20 plasmids pMOG236, pMOG249 or pMOG250, via the method described by Hoekema et al., (1989). In total, 75 transgenic plants were regenerated from shoots that had developed on selection medium (100 mg/l kanamycin), viz. 51 plants with construct pMOG236, 12 with pMOG249 and 12 with pMOG250. The transgenic plants were
25 multiplied in vitro, after which they were grown in pot soil into adult plants for analyses.

V Detection of HSA-mRNA and HSA-protein

30 All transgenic potato plants were tested for the presence of HSA-mRNA (Verwoerd et al., 1989) using Northern blotting. In 46 of the 51 pMOG236, 10 of the 12 pMOG250 and all pMOG249 transgenic plants, HSA-mRNA was detected.

The presence of HSA-protein was tested by separating the
35 soluble protein fraction on 7.5-15% SDS-polyacrylamide gradient gels, followed by Western blotting on nitrocellulose and immunodetection with goat-antiHSA (Sera-Lab, USA) followed by

rabbit-anti-goat peroxidase. The binding conditions during the incubation of nitrocellulose with antibodies were 10 mM NaPi, pH 7.2, 150 mM NaCl, 1.25% Blotto, 0.2% Tween 20, 0.1% Triton X100, 35°C. HSA was visualized with a peroxidase staining with
5 o-dianisidine. Detectable amounts of HSA were found in 31 pMOG236, 8 pMOG249 and 9 pMOG250 plants, namely in leafs, stems and tubers.

VI Excretion of HSA by plant cells

10

After transformation, both synthesis and excretion of HSA by transgenic plants could be shown. It appeared, that each of the signal peptides used was capable of excreting HSA from the plant cell. Excretion could be shown in three ways:

- 15 a) Following electroporation of tobacco protoplasts with the above mentioned vectors and subsequent transient expression of the introduced gene and signal sequence, HSA could be specifically detected in the culture medium after a culture period of 48 hours, using Western blotting. To this end, the
20 medium was desalted on a PD10/G25 column and concentrated by freeze-drying. In extracts of transgenic tobacco protoplasts (after lysis of the pelleted protoplasts in 2x concentrated SDS-sample buffer) the HSA was below the detection level (< 1 ng HSA/25 µg soluble protein).
- 25 b) In the medium of suspension cells of transgenic tobacco, HSA could be detected using Western blotting (2 ng/10 µg extracellular protein). In extracts of pelleted suspension cells the HSA level was on the detection level of 1 ng HSA/25 µg soluble protein.
- 30 c) Through analysis of the extracellular fluid in transgenic leaf material of potato plants. It appeared possible to extract extracellular fluid after vacuum-filtration of leaf slices in 5 mM Hepes, pH 6.3, 50 mM NaCl, followed by slow centrifugation (600 g) (Hendriks *et al.*, 1985). This fluid could be identified
35 as such by determination of the specific activity of the marker enzymes glucose-6P dehydrogenase (cytoplasmatic) and peroxidase. According to the Western blotting analysis, it appeared that the

extracellular fluid contained approximately a 20x higher HSA-concentration (per mg protein) than a total leaf extract. From leaves of transgenic tobacco plants with the construct pMOG285, containing the HSA-gene without signal peptide, the
5 extracellular fluid was extracted as described for potato plants. In this fluid no HSA could be detected.

VII In vivo processing of HSA

- 10 To investigate whether HSA was processed correctly during the transport through the plant cell, during which the corresponding signal peptide has to be cleaved off in front of the Asp-codon of mature HSA (fig.1), various experiments were carried out. Since HSA has no enzymatic function, only physical
15 properties could be analysed, whereby plant HSA could be compared with standard HSA (the analysis procedures used are described in detail in VIII - X):
- a) the molecular weight was compared using FPLC-gel filtration and SDS-PAGE (7.5-15% gradient gels).
 - 20 b) The elution pattern during a salt gradient on monoQ anion exchanger (0 -> 350 mM NaCl in 50 mM Tris pH 8.0).
 - c) CNBr digestions of purified HSA were analysed on 20-27% SDS-PAGE gradient gels after silver staining.
 - d) amino acid sequence of HSA purified from transgenic plants.
 - 25 The only differences that could be found consisted of differences in the N-terminal amino acid sequence, depending on the signal peptide used (see IX), and differences in the CNBr-digestion pattern.

30 VIII Purification of HSA from transgenic potato plants

From the clones with the highest expression, one from each construct (236#31, 249#10 and 250#6), enough transgenic plants were grown for the extraction of HSA. For this purpose 500-1000
35 gram plant material was homogenised in 10 mM NaPi pH 7.2, 150 mM NaCl (PBS) with 0.6% PVPP, 0.1 mM PMSF, 1 mM EDTA at 4°C. The soluble fraction was freed from cell debris and incubated with

anti-HSA coupled to 1.5 ml Reactigel HF-65 (Pierce Chemicals) and 0.5% Tween 80, during 4 h. The HSA-anti-HSA-Reactigel complex was isolated by centrifugation, transferred to a 2ml column and rinsed twice with 0.5% Tween 80 in PBS. Desorption of HSA was carried out by elution with 0.1 M glycine, pH 2.5, 10% dioxan, after which the buffer was quickly exchanged by 50 mM Tris, pH 8.0 using a PD10/G25 column (Pharmacia). The eluate was directly filtered (0.22 µm) and transferred to a MonoQ column (HR5/5 Pharmacia). By means of a linear gradient (0 to 350 mM NaCl in 50 mM Tris/HCl pH 8.0 in 20 minutes, 1 ml/min) HSA was for the most part purified from the aspecifically bound protein components. The fractions that appeared to have a high concentration of HSA in a Western blot, were concentrated by freeze-drying and loaded on HR10/30 Superose 6 gel filtration column (Pharmacia) in PBS. The elution volume of HSA isolated from transgenic plants corresponded exactly with the elution volume of standard HSA, in both columns. The purity of the isolated HSA was confirmed with a silver-stained SDS-gel.

IX N-terminal amino acid sequence of HSA from transgenic plants

The HSA-peak of the Superose 6 gel filtration column (VIII) was directly spotted on Immobilon PVDF membrane for amino acid sequence analysis using an Applied Biosystems 477A Protein Sequencer (Eurosequence B.V., Groningen). Unexpectedly, only HSA from pMOG250 plants appeared to have been correctly processed; the amino acid sequence at the N-terminus of purified HSA was established as Asp-Ala-His-Lys-Ser-Glu. This sequence fully represents the N-terminal sequence of correctly processed HSA, present in human blood plasma (Lawn *et al.*, 1981).

The amino acid sequence of the N-terminus of HSA, purified from pMOG236 plants (i.e. the construct with the human signal peptide) demonstrated that the excreted HSA still contained a propeptide: Arg-Gly-Val-Phe-Arg-Arg. Only the propeptide of 18 amino acids had been cleaved off. In humans, the propeptide is cleaved off during a late phase of the excretion process, by

means of a serine protease (Brennan et al, 1984). This class of proteinases is rare in plants (Ryan & Walker-Simmons, 1981).

HSA, purified from transgenic plants pMOG249, appeared chemically blocked for Edman-degradation at the N-terminus, possibly due to the presence of the Ala-residue (Persson et al., 1985) which originates from the signal peptide construct that was used (cf. fig.1).

X Cyanogen bromide digestion of HSA from transgenic plants

10

Purified HSA (VIII) on PVDF membrane was used as starting material for CNBr digestion. The desorption from the membrane was carried out with 50 mM Tris/HCl, pH9, 2% SDS, 2% Triton X100, followed by cold acetone precipitation. The dried pellet was resuspended in 10 µl 70% formic acid with 200 nmol CNBr/µg protein and incubated at room temperature during 24 hours. After dilution, the digest was freeze-dried and analysed on 20-27% SDS-PAGE according to Giullan et al., (1983). In this experiment it appeared, that only the digest derived from HSA, isolated from transgenic pMOG236, showed a deviant pattern in comparison with the digest of the standard HSA. Very likely, this is a result of the presence of the propeptide preceding the HSA, as appeared from the amino acid sequence data (see IX).

15

20

References

- Baulcombe, Saunders, Bevan, Mayo, Harrison (1986) Nature 321, 446-449
- 5 Bevan (1984) Nucl Acid Res 12, 8711-8721
- Bherens, Spiekerman, Brown (1975) Fed Proc 34, 591
- 10 Brederode, Koper-Zwarthoff, Bol (1980) NAR 8, 2213-2223
- Brennan, Owen, Boswell, Lewis, Carrell (1984) Biochem Biophys Acta 802, 24-28
- 15 Carlson, Botstein (1982) Cell 28, 145-154
- Chen, Varner (1985) EMBO J 4, 2145-2151
- 20 Cornelissen, Hooft van Huijsduijnen, Bol (1986) Nature 321, 531-532
- Della-Cioppa, Kishore, Beachy, Fraley (1987) Plant Physiol 84, 965-968
- 25 De Loose, Alliotte, Gheysen, Gielen, Soetaert, Van Montagu, Inze (1988) Gene 70, 13-23
- Ditta, Stanfield, Corbiu, Helinski (1980) Proc Nat Acad Sci, USA 77, 7347-7351
- 30 Dorel, Voelker, Herman, Chrispeels (1989) J Cell Biol 108, 327-337
- Etcheverry, Forrester, Hitzeman (1986) Bio/Techn 4, 726-730
- 35 Giuilan, Moss, Greaser (1983) Anal Biochem 129, 277-287
- Goodman, Knauf, Houck, Comai (1987) PCT/WO 87/00865
- 40 Guilley, Dudley, Jonard, Balazs, Richards (1982) Cell 30, 763-773
- Harkki, Uusitalo, Bailey, Penttila, Knowles (1989) Bio/Techn 7, 596-603
- 45 Hendriks, Van den Berg, Schram (1985) Planta 164, 89-95
- Herskowitz, Oshima (1982) in: The molecular biology of the yeast Saccharomyces Vol. 1, 181-210
- 50 Hoekema, Hirsch, Hooykaas, Schilperoort (1983) Nature 303, 179-180
- 55 Hoekema, Huisman, Molendijk, Van den Elzen, Cornelissen (1989) Bio/Techn 7, 273-278

- Hooft van Huijsduijnen, Cornelissen, Van Loon, Van Boom, Tromp,
Bol (1985) EMBO J 4, 2167-2171
- 5 Horsch, Fry, Hoffmann, Wallroth, Eichholtz, Rogers, Fraley
(1985) Science 225, 1229-1231
- Jefferson (1987) Plant Mol Biol Report 5, 387-405
- Johnsson, Bankaitis, Emr (1987) Cell 48, 875-885
- 10 Judah, Gamble, Steadman (1973) Biochem J 134, 1083-1091
- Kingsman, Kingsman, Mellor (1987) Trends in Biotechn 5, 53-56
- 15 Kornfeld (1987) Fed Am Soc Exp Biol J 1, 462-468
- Kunkel (1985) Proc Nat Acad Sci, USA 82, 488-492
- Latta, Knapp, Sarmientos, Brefort, Becquart, Guerrier, Jung,
20 Mayaux (1987) Bio/Techn 5, 1309-1314
- Lawn, Adelman, Bock, Franke, Houck, Najarian, Seeburg, Wion
(1981) Nucl Acid Res 9, 6103-6114
- 25 Maniatis, Fritsch, Sambrook (1982) Molecular Cloning, Cold
Spring Harbour Lab
- Memelink (1988) Altered gene expression in T-DNA transformed
tobacco tissues. Thesis, Rijksuniversiteit Leiden
- 30 Misra (1989) Plant. Physiol 89, S47
- Persson, Flinta, Heijne, Jörnval (1985) Eur J Biochem 152, 523-
527
- 35 Pfeffer, Rothman (1987) Ann Rev Biochem 56, 829-852
- Rodenburg, De Groot, Schilperoort, Hooykaas (1989) Plant Mol
Biol (submitted)
- 40 Ryan, Walker-Simmons (1981) Plant Proteinases. In: The
Biochemistry of Plants, Stumpf, Conn (eds) Acad Press. New York
- Saunders, Guyer (1987) EP-A-0229712
- 45 Sleat, Gallie, Jefferson, Bevan, Turner, Wilson (1987) Gene 217,
217-225
- Stetler, Forsyth, Gleason, Wilson, Thompson (1989) Bio/Techn 7,
55-60
- 50 Verwoerd, Dekker, Hoekema (1989) Nucl Acid Res 17, 2362
- Yanisch-Perron, Vieira, Messing (1985) Gene 33, 103-119
- 55

Claims

1. A process for the production in a plant host of heterologous protein material which is to be excreted from the cells in which it is produced, by growing plants or plant cells that, by means of genetic manipulation, optionally of an ancestor, using a recombinant polynucleotide, have been provided with the genetic information which is required to allow the plant host to express the heterologous protein material and excrete it from the cells in which it is formed, the genetic information introduced into the host comprising an expression cassette that is functional in the host and contains at least a gene coding for the mature protein material, directly preceded by genetic information coding for a plant signal peptide that is functional in the host.
2. A process according to claim 1, in which a protein material is produced that in its natural environment originates from a precursor which contains a signal peptide that provides for excretion from the cell and which itself is cleaved off, the genetic information introduced into the plant host comprising an expression cassette which is functional in the host and contains a gene construct comprising a gene encoding the mature protein material and, directly preceding it, genetic information coding for a plant signal peptide that is functional in the host, instead of the genetic information coding for the natural signal peptide of the heterologous protein material.
3. A process according to claim 1 or 2, in which the genetic information introduced into the plant host comprises an expression cassette that is functional in the host and contains a gene construct comprising a gene encoding the mature protein material and, directly preceding it, genetic information coding for a plant signal peptide that is functional in the host and is derived from the pathogenesis-related protein PROB12.

4. A process according to any of the claims 1-3, in which a plant of a species that is suitable for the production of starch is used as said plant host.
5. A process according to claim 4, in which a plant species, selected from the group consisting of potato, maize and cassava is used as said plant host.
6. A process according to claim 5, in which a potato variety that is useful for industrial starch production is used as said plant host, and its tubers are used both for the production of starch and for the production of the heterologous protein material.
7. A process according to any of the claims 1-3, in which a suspension culture of plant cells is used as said plant host.
8. A process according to claim 7, in which a suspension culture of plant cells of the plant species tobacco is used as said plant host.
9. A process according to any of the claims 1-8, in which the protein material produced is an animal or human protein which requires one or more post-translational processing steps, among which at least an excretion from the cells in which the protein is produced in the form of a precursor which comprises a signal peptide preceding the mature protein, and a cleavage of this signal peptide.
10. A process according to claim 9, in which the protein material produced is human serum albumine.
11. A process for the production of human serum albumine by growing potato plants that, by means of genetic manipulation, optionally of an ancestor, using a recombinant polynucleotide, have been provided with the genetic information required to allow expression and correct post-translational processing of the human serum albumine by the potato plants, the genetic information introduced into the potato comprising an expression cassette that is suitable for the potato and contains at least a gene encoding mature human serum albumine, directly preceded by genetic information coding for a plant signal peptide that is functional in the potato and is derived from the pathogenesis related protein PROB12, and isolating the human serum albumine

produced by the genetically manipulated potato plants from the potato tubers.

12. A process for the production of human serum albumine by growing in suspension, cells of the plant species tobacco that, by means of genetic manipulation, optionally of an ancestor, using a recombinant polynucleotide, have been provided with the genetic information required to allow expression and correct post-translational processing of the human serum albumine by the suspended tobacco cells, the genetic information introduced into the tobacco comprising an expression cassette that is suitable for tobacco and contains at least a gene encoding mature human serum albumine, directly preceded by genetic information coding for a plant signal peptide that is functional in plants and is derived from the pathogenesis-related protein PROB12, and isolating the human serum albumine produced by the genetically manipulated suspended tobacco cells from the culture medium.
13. Plants, plant parts and plant cells that, by means of genetic manipulation, optionally of an ancestor, using a recombinant polynucleotide, have been provided with the genetic information that is necessary to allow the plants, plant parts, or plant cells to express a heterologous protein material and excrete it from the cells in which it is formed, the genetic information introduced into the plant host comprising an expression cassette which contains at least a gene encoding the mature protein material, directly preceded by genetic information coding for a plant signal peptide that is functional in the host.
14. Plants, plant parts and plant cells according to claim 13, capable of producing a heterologous protein material that, in its natural environment, originates from a precursor which comprises a signal peptide that provides for excretion from the cell and which itself is cleaved off, the genetic information introduced into the plant host comprising an expression cassette which contains a gene construct comprising a gene encoding the mature protein material and, directly preceding it, genetic information coding for a plant signal peptide that is functional

in the host, instead of the genetic information coding for the natural signal peptide of the heterologous protein material.

15. Plants, plant parts and plant cells according to claim 13 or 14, in which the genetic information introduced into the
- 5 plant host comprises an expression cassette containing a gene construct which comprises a gene encoding the mature protein material and, directly preceding it, genetic information coding for a plant signal peptide that is functional in the host and is derived from the pathogenesis-related protein PROB12.
- 10 16. Plants, plant parts and plant cells according to any of the claims 13-15, selected from a group of plant species that are suitable for the production of starch.
17. Plants, plant parts and plant cells according to claim 16, selected from the group of plant species consisting of potato,
- 15 maize and cassava.
18. Plants, plant parts and plant cells according to claim 17, selected from a group consisting of potato varieties that are suitable for industrial production of starch.
19. Plants, plant parts and plant cells according to any of the
- 20 claims 13-15, being a species that is suitable for culturing in suspension.
20. Plants, plant parts and plant cells according to claim 19, selected from the group consisting of Nicotiana species.
21. Plants, plant parts and plant cells according to any of the
- 25 claims 13-20, in which the heterologous protein material is an animal or human protein which requires one or more post-translational processing steps, among which at least an excretion from the cells in which it is produced in the form of a precursor which comprises a signal peptide directly preceding
- 30 the mature protein, and a cleavage of this signal peptide.
22. Plants, plant parts and plant cells according to claim 21, in which the heterologous protein material is human serum albumine.
23. Potato plants, as well as parts and cells thereof, suitable
- 35 for the production of human serum albumine due to the fact that they have been provided, by means of genetic manipulation, optionally of an ancestor, using a recombinant polynucleotide,

with the genetic information that is necessary to allow the plants, plant parts, or plant cells to express and correctly process the human serum albumine, the genetic information introduced into the potato comprising an expression cassette
5 containing at least a gene encoding mature human serum albumine, directly preceded by genetic information coding for a plant signal peptide that is functional in the potato and is derived from the pathogenesis-related protein PROB12.

24. Tobacco plants, as well as parts and cells thereof, suitable for the production of human serum albumine due to the fact that they have been provided, by means of genetic manipulation, optionally of an ancestor, using a recombinant polynucleotide, with the genetic information that is necessary to allow expression and correct post-translational processing of
10 the human serum albumine by the plants, plant parts, or plant cells, the genetic information introduced into the tobacco comprising an expression cassette that is suitable for tobacco and contains at least a gene encoding mature human serum albumine, directly preceded by genetic information coding for a
15 plant signal peptide which is functional in the host and is derived from the pathogenesis-related protein PROB12.

25. Protein material, obtained by means of a process according to any of the claims 1-12 and/or obtained from plants, plant parts or plant cells according to any of the claims 13-24.

26. Human serum albumine, obtained by means of a process according to any of the claims 1-12 and/or obtained from plants, plant parts or plant cells according to any of the claims 13-24.

27. Recombinant polynucleotide, comprising a gene encoding an animal or human protein in its mature form, as well as, directly
30 preceding the gene, genetic information encoding a plant signal peptide.

28. Recombinant polynucleotide according to claim 27, in which the genetic information, coding for the plant signal peptide, is genetic information coding for the plant signal peptide derived
35 from the pathogenesis-related protein PROB12.

29. A recombinant polynucleotide according to claim 27 or 28, in which the gene coding for an animal or human protein in its mature form, is a gene encoding mature human serum albumine.
30. A recombinant polynucleotide according to any of the claims 27-29, in which the gene encoding an animal or human protein in its mature form, and the genetic information directly preceding it and coding for a plant signal peptide, are incorporated in an expression cassette that is suitable for the host.
31. A recombinant polynucleotide according to claim 30, in which the expression cassette that is suitable for the host, is an expression cassette that is suitable for potato, maize, cassava, or tobacco.
32. A recombinant polynucleotide according to any of the claims 27-31, in which the polynucleotide consists of DNA.
33. A recombinant DNA according to claim 32, comprising a vector plasmid and an expression cassette inserted therein, said expression cassette comprising a gene encoding an animal or human protein in its mature form, and, directly preceding it, genetic information coding for a plant signal peptide.
34. A recombinant DNA according to claim 33, in which the vector plasmid is a vector that is suitable for cloning in a bacterial host.
35. A recombinant DNA according to claim 33, in which the vector plasmid is a vector that is suitable for the host.

1/5




FIG.1

SUBSTITUTE SHEET

2/5




FIG. 2

SUBSTITUTE SHEET

3/5




FIG. 3

SUBSTITUTE SHEET

SYNTHETIC PROB12 SIGNALPEPTIDE SEQUENCE

(N) S C B
 CATGAACTTCCTC AAAAGCTTCCGC TTTT ATGCTTCCTTT GTTTT GGCCAATAC TTTGTAGCTGTTACGCA TGCTCSAGATCGATG
 TTTGAAGGAGTTTT CGAAGGGGAAATACGGAAGGAAACAAACCGTT ATGAACATCGACAATGCGTACGAGCTC TAGCTACCTAG




FIG. 4

SUBSTITUTE SHEET

5/5




FIG. 5

SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No PCT/NL 90/00108

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁵ : C 12 N 15/62, C 12 N 15/82, C 12 P 21/02, C 12 N 15/14, C 12 N 15/29, C 12 N 5/10, A 01 H 5/00		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
IPC ⁵	C 12 N, C 12 P, A 01 H	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	EP, A, 0255153 (UNILEVER) 3 February 1988 see page 33, lines 22-25 --	1,7,8,13,19, 20,25
T	Plant Molecular Biology, vol. 15, 1990 Kluwer Academic Publishers, (BE), K. Düring et al.: "Synthesis and self-assembly of a functional monoclonal antibody in transgenic Nicotiana tabacum", pages 281-293, see page 282, left-hand column, paragraph 3; page 290, left-hand column, paragraph 4; page 292, ref. 13 and ref. 14 --	2,13,27, 30-33,35
X	EP, A, 0270248 (ICI) 8 June 1988 see the whole document, particularly	1,2
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
2nd November 1990	14. 12. 90	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	<div style="display: flex; align-items: center;"> <div style="border: 1px solid black; padding: 2px 5px; margin-right: 10px;">M. PEIS</div> <div style="font-family: cursive; font-size: 1.2em;">M. Peis</div> </div>	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, " with indication, where appropriate, of the relevant passages	Relevant to Claim No.
	page 10, lines 42-43 --	
X	EP, A, 0308381 (SKANDIGEN) 22 March 1989 see pages 91-101 --	26
P,X	WO, A, 90/01551 (ROGERS) 22 February 1990 see examples 1,2; particularly page 14, line 27 - page 15, line 4; page 20, lines 21-34; page 25, lines 4-17 --	2,4,13,14, 16,19,25
P,X	WO, A, 90/10076 (MONSANTO) 7 September 1990 see example 11 --	2,13,14
P,X	EP, A, 0332104 (CIBA-GEIGY) 13 September 1989 see page 19, lines 15-36; examples 16,34-39 --	2,13,14,20
P,X	WO, A, 89/12386 (CALGENE) 28 December 1989 see examples 7,8 --	2,13,14
Y	EP, A, 0307841 (GENERAL HOSPITAL CORP.) 22 March 1989 see page 5, line 55 - page 6, line 11; page 6, lines 32-38 --	3,15,9
Y	Nature, vol. 321, 29 May 1986, B.J.C. Cornelissen et al.: "A tobacco mosaic virus-induced tobacco protein is homologous to the sweet-tasting protein thaumatin", pages 531-532, see figure 3 --	3,15,9

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, " with indication, where appropriate, of the relevant passages	Relevant to Claim No.
P,X	Bio/Technology, vol. 8, March 1990, P.C. Sijmons et al.: "Production of correctly processed human serum albumin in transgenic plants", pages 217-221, see the whole article --	1-35
A	WO, A, 87/00865 (CALGENE) 12 February 1987 see pages 5,6, claim 1 --	9,21,27,30-35
A	EP, A, 0091527 (HARVARD COLLEGE) 19 October 1983 see claims 14,15 --	10-12,22-29
A	Journal of Cellular Biochemistry, suppl. 13D, 27 March - 7 April 1989, Alan R. Liss, Inc., (New York, US), J.E. Passiatore et al.: "Influence of a plant transit peptide on bacterial chitinase activity in tobacco", page 267, abstract M 145, see abstract -----	3,15,9

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

NL 9000108
SA 39071

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 07/12/90. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0255153	03-02-88	AU-A- 7513287	11-01-88
		WO-A- 8707641	17-12-87
		JP-T- 1500242	02-02-89
EP-A- 0270248	08-06-88	AU-A- 8110487	12-05-88
		JP-A- 63141591	14-06-88
WO-A- 8700865	12-02-87	US-A- 4956282	11-09-90
		AU-A- 6196686	05-03-87
		EP-A- 0233915	02-09-87
		JP-T- 63500425	18-02-88
EP-A- 0091527	19-10-83	None	

FORM 1007

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82